DLBS 1033 clinical trials
Also written DLBS1033.
How each study uses DLBS 1033 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the DLBS 1033 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
16 studies that test it; most in 2012 (2)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 1 |
| 2020 | 1 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 8
Dexa Medica Group (8) · Universitas Sebelas Maret (4) · Indonesia University (2) · RS H Adam Malik (1) · Duta Wacana Christian University (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test DLBS 1033.
- Feb 2027DLBS1033 as Adjunctive Therapy for Patients With Diabetic NeuropathyNot applicable · RS H Adam Malik
Studies
Open first, then newest update. How each study uses DLBS 1033 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 16
- DLBS1033 as Adjunctive Therapy for Patients With Diabetic NeuropathyNot yet recruitingNot applicableRS H Adam MalikNCT07683598Written as DLBS1033How we know
- The Effect of Oral DLBS1033 in Patients With Diabetic PolyneuropathyNot yet recruitingPhase 2/3Universitas Sebelas MaretNCT07475065Written as DLBS1033How we know
- Effects of Lumbrokinase DLBS1033 on D-Dimer, Interleukin-6, and Clinical Outcomes in Patients With Pneumonia and SepsisCompletedPhase 2Universitas Sebelas MaretNCT07892794Written as DLBS1033How we know
- Oral DLBS1033 as Adjunctive Therapy in Acute Ischemic Stroke: Impact on Inflammatory Biomarkers and OutcomesCompletedPhase 4Universitas Sebelas MaretNCT07121569Written as Oral lumbrokinase DLBS1033How we know
- Comparing Oral Lumbrokinase DLBS1033 and Betahistine Mesylate in Benign Paroxysmal Positional VertigoCompletedPhase 4Universitas Sebelas MaretNCT07075289Written as DLBS1033How we know
- DLBS1033 for Acute Ischemic Stroke PatientsTerminatedPhase 2/3Dexa Medica GroupNCT02133521Written as DLBS1033How we know
- Effect of DLBS1033 After Primary PCI in Patients With STE-ACSTerminatedPhase 2/3Dexa Medica GroupNCT02976701Written as DLBS1033How we know
- The Benefit of Add On DLBS1033 for Ischemic Stroke PatientStatus unknownPhase 2/3Duta Wacana Christian UniversityNCT04425590Written as DLBS1033How we know
- DLBS1033 Treatment in Diabetic With Peripheral Arterial DiseaseTerminatedPhase 2/3Dexa Medica GroupNCT02145988Written as DLBS1033How we know
- The Effects of DLBS1033 on Haemostasis Parameters in Healthy VolunteersCompletedPhase 2Indonesia UniversityNCT01694537Written as DLBS1033How we know
- Biological Half Life of DLBS1033 in Healthy VolunteersCompletedPhase 1/2Indonesia UniversityNCT01905878Written as DLBS1033How we know
- DLBS1033 for the Treatment of Acute Ischemic StrokeTerminatedPhase 3Dexa Medica GroupNCT02362984Written as DLBS1033How we know
- Efficacy and Safety of DLBS1033 in Subjects With Type 2 Diabetes MellitusCompletedPhase 4Dexa Medica GroupNCT01865474Written as DLBS1033How we know
- DLBS1033 for Acute NSTEMI Without Early Coronary RevascularizationWithdrawnPhase 2/3Dexa Medica GroupNCT02146664Written as DLBS1033How we know
- Efficacy of DLBS1033 in Patients With Acute Ischemic StrokeCompletedPhase 3Dexa Medica GroupNCT01790997Written as DLBS1033How we know
- Safety and Efficacy of DLBS1033 in Healthy SubjectsCompletedNot applicableDexa Medica GroupNCT01378585Written as DLBS1033How we know
What changed recently
From the registry's own updates since Oct 20, 2026.
Newly registered1
Codes
What other systems call DLBS 1033 · ClinicalTrials.gg INT005853
- MeSH (NLM) C559131DLBS 1033One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C559131 | DLBS 1033 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.